Market Analysts see Salesforce Inc. [CRM] falling to $140. Time to buy?

Salesforce Inc. [NYSE: CRM] price plunged by -0.70 percent to reach at -$1.04. The company report on January 12, 2023 that New Salesforce for Retail Innovations Help Personalize Every Shopping Moment.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Casey’s and Duluth Trading Co. are using Salesforce to connect to their customers in a whole new way.

New research shows 65% of consumers will remain loyal to companies if they offer more personalized experiences.

A sum of 9396952 shares traded at recent session while its average daily volume was at 9.43M shares. Salesforce Inc. shares reached a high of $150.49 and dropped to a low of $146.10 until finishing in the latest session at $148.47.

The one-year CRM stock forecast points to a potential upside of 22.07. The average equity rating for CRM stock is currently 2.00, trading closer to a bullish pattern in the stock market.

Guru’s Opinion on Salesforce Inc. [CRM]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CRM shares is $190.52 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CRM stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Atlantic Equities have made an estimate for Salesforce Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on January 13, 2023. While these analysts kept the previous recommendation, Bernstein dropped their target price from $134 to $119. The new note on the price target was released on January 11, 2023, representing the official price target for Salesforce Inc. stock. Previously, the target price had yet another drop from $200 to $150, while Robert W. Baird kept a Neutral rating on CRM stock.

The Average True Range (ATR) for Salesforce Inc. is set at 4.93, with the Price to Sales ratio for CRM stock in the period of the last 12 months amounting to 4.90. The Price to Book ratio for the last quarter was 2.49, with the Price to Cash per share for the same quarter was set at 11.91. Price to Free Cash Flow for CRM in the course of the last twelve months was 26.73 with Quick ratio for the last quarter at 1.10.

CRM Stock Performance Analysis:

Salesforce Inc. [CRM] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.93. With this latest performance, CRM shares gained by 10.18% in over the last four-week period, additionally sinking by -11.57% over the last 6 months – not to mention a drop of -35.06% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CRM stock in for the last two-week period is set at 61.52, with the RSI for the last a single of trading hit 67.54, and the three-weeks RSI is set at 56.75 for Salesforce Inc. [CRM]. The present Moving Average for the last 50 days of trading for this stock 141.89, while it was recorded at 147.98 for the last single week of trading, and 163.25 for the last 200 days.

Insight into Salesforce Inc. Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and Salesforce Inc. [CRM] shares currently have an operating margin of +2.07 and a Gross Margin at +65.65. Salesforce Inc.’s Net Margin is presently recorded at +5.45.

Return on Equity for this stock inclined to 2.90, with Return on Assets sitting at 1.75.

Salesforce Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.10 and a Current Ratio set at 1.10.


The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CRM. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Salesforce Inc. go to 18.30%.

Salesforce Inc. [CRM] Insider Position Details

There are presently around $112,806 million, or 79.50% of CRM stock, in the hands of institutional investors. The top three institutional holders of CRM stocks are: VANGUARD GROUP INC with ownership of 80,449,523, which is approximately 1.391% of the company’s market cap and around 0.10% of the total institutional ownership; BLACKROCK INC., holding 68,810,159 shares of the stock with an approximate value of $10.22 billion in CRM stocks shares; and STATE STREET CORP, currently with $6.66 billion in CRM stock with ownership of nearly 1.324% of the company’s market capitalization.

Positions in Salesforce Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 977 institutional holders increased their position in Salesforce Inc. [NYSE:CRM] by around 47,134,900 shares. Additionally, 1,041 investors decreased positions by around 55,302,170 shares, while 203 investors held positions by with 657,354,947 shares. The mentioned changes placed institutional holdings at 759,792,017 shares, according to the latest SEC report filing. CRM stock had 125 new institutional investments in for a total of 12,600,521 shares, while 161 institutional investors sold positions of 4,501,503 shares during the same period.


Please enter your comment!
Please enter your name here